Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | PPARD | Q03181 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203583 | 0.92 | ACVR1 (0.36) | ACVR1L3MBTL1BRD4PDE4APDE4B | |
| SCHEMBL2204437 | 0.90 | FTO (0.39) | ACVR1L3MBTL1BRD4PPARGPPARD | |
| SCHEMBL2203656 | 0.86 | ACVR1 (0.36) | ACVR1L3MBTL1BRD4PDE4APDE4B | |
| SCHEMBL2209188 | 0.83 | PPARG (0.39) | ACVR1L3MBTL1BRD4PDE4APDE4B | |
| SCHEMBL2203638 | 0.82 | FTO (0.42) | ACVR1L3MBTL1BRD4PDE4APPARG | |
| SCHEMBL2203177 | 0.82 | KMT2A (0.39) | ACVR1L3MBTL1BRD4KMT2A | |
| SCHEMBL2206510 | 0.82 | ACVR1 (0.37) | ACVR1L3MBTL1BRD4PDE4APDE4B | |
| SCHEMBL2206933 | 0.82 | ACVR1 (0.37) | ACVR1L3MBTL1BRD4PDE4APDE4B | |
| SCHEMBL2209287 | 0.81 | L3MBTL1 (0.36) | ACVR1L3MBTL1BRD4PDE4APDE4B | |
| SCHEMBL3124914 | 0.81 | L3MBTL1 (0.38) | ACVR1L3MBTL1BRD4PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | ACVR1 255/4885L3MBTL1 4249/4885BRD4 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.